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Abstract
Background: Repeatability and reproducibility are essential for clinicians for several purposes. Although
discouraged, use of the Coefficient of Variation (CV) for assessing repeatability and reproducibility, rather than the
Intraclass Correlation Coefficient (ICC), is still widespread. The aim of the present study was to highlight how using
inappropriate indices may lead to misleading results, and this is done by simulation study and using real data on
Anterior Active Rhinomanometry (AAR) in both healthy children and ones with rhinitis.
Methods: A simulation study was carried out to highlight how using inappropriate indices could be misleading.
Then a comparison was made between CV and ICC to assess repeatability and reproducibility of AAR, for which
previous studies have given underestimated results. AAR is recommended as the gold standard tool for measuring
nasal resistance in clinical practice.
Results: A simulation study showed that the ICCs estimated from data generated assuming a true CV yielded
results in agreement with estimated CVs; by contrast, if data were generated assuming a true ICC, CVs yielded
conflicting results. For AAR, ICCs showed good repeatability, whereas CVs showed unacceptable repeatability. AUC
and 95% CI for AAR showed good performance in predicting current symptoms of rhinitis in the overall study
population.
Conclusions: The present study focused on the importance of the choice of appropriate indices of repeatability
and reproducibility, demonstrating the repeatability of AAR in both healthy children and ones with rhinitis.
Trial registration: ClinicalTrials.gov (ID: NCT03286049; Registration Date: September 15, 2017; Actual Study Start
Date: January 10, 2018).
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Background
Repeatability of measurements refers to the variation
in repeated measurements made on the same subject
under identical conditions. Variability in measure-
ments made on the same subject in a repeatability
study can then be ascribed only to errors due to the
measurement process itself [1]. By contrast, when the
measurements are performed under changing condi-
tions, i.e. over a period of time, reproducibility is
assessed. Repeatability and reproducibility are essential
for clinicians for a variety of purposes [2, 3], such as
aiding diagnosis, predicting future patient outcomes
and choosing a personalized therapy. Several statis-
tical methods have been developed and recommended
for assessing repeatability and reproducibility, i.e.
Intraclass Correlation Coefficient (ICC) and Bland
Altman plot, whereas others have been discouraged,
for example Pearson’s correlation and Coefficient of
Variation (CV) [1, 4, 5].
This paper was motivated by a study on Anterior
Active Rhinomanometry (AAR) in healthy children
and in ones with rhinitis. AAR is recommended as
the gold standard tool for measuring nasal ventilation
during a normal respiratory cycle and resistance at
the nostrils in patients with upper airway obstruction
symptoms [5, 6]. In clinical practice, AAR is the most
widely used and readily applicable test for assessing
the degree of nasal obstruction, as well as for moni-
toring clinical outcomes after surgical or medical pro-
cedures in order to improve nasal patency [7]. The
test execution procedure is standardized according to
the International Committee on Standardization of
Rhinomanometry [6], with subjects sitting in upright
positon and wearing a face mask, where breathe only
with the nose and close their mouth.
To date, few studies investigating AAR repeatability
have been performed in adults only, showing contro-
versial results [8–10]. In particular, Carney et al. ob-
served that single measurements had an unacceptably
high CV (19–60%) in a cross-sectional study on seven
adults [9], and Thulesius et al. reported rather poor
long-term reproducibility (CV 27%) in a longitudinal
study over 5 months on nine healthy adults [10]. Con-
versely, Silkoff et al. reported a high level of repeat-
ability (coefficient of variation, CV 8.5 ± 2.8%) and
Intraclass Correlation Coefficient (ICC) 0.96 in a
small sample of healthy subjects [8].
The aim of the present study was to highlight the fact
that using inappropriate tools may lead to misleading re-
sults, and this was done by comparing the ICC, the
Bland Altman plot and the CV for data from both
healthy children and ones with rhinitis and by a simula-
tion study, as a possible reference for clinicians dealing
with this type of study.
Methods
Statistical tools and underlying assumptions
This section is devoted to introducing the statistical
tools used in the simulation and clinical data. The ICC
can be defined as the ratio of the between-subject vari-
ance to the sum of the within-subject and between-
subject variances, and can be derived from a two-level





The ICC ranges from 0 to 1 and the following bench-
marks can be used for interpretation: ICC < 0.20 “poor
agreement”, 0.21–0.40 “fair agreement”, 0.41–0.60 “mod-
erate agreement”, 0.61–0.80 “substantial agreement”,
and > 0.80 “excellent agreement” [12–14]. In order to de-
tect at least “fair agreement”, a significance test [15] can
be performed to assess the following hypotheses:
H0 : ICC≤0:20
H1 : ICC > 0:20

The ICC suffers from a variety of methodological is-
sues including sensitivity to assumptions of normality
and equal variance [16, 17], and its use under assump-
tion violations leads to misleading and likely inflated es-
timates of interrater reliability [18].
The CV is defined as the ratio between the standard
deviation and the mean:
CV i ¼ σ iμi
where σi and μi are, respectively, the standard devi-
ation and the mean of the measurement for subject i.
CV is subject to some restrictions; for example it is
meaningful only for measurements with a real zero
(i.e., “ratio scales”). In addition, the values of the
measurement to compute the CV always have to be
positive [19]. The levels of acceptability for the CV
depend on the field of application [20, 21]; however,
CV < 15% is widely used [9, 10].
The Bland-Altman plot is used to assess the agreement
between two repeated measurements [22] and to visually
check possible heteroscedasticity of the data. Heterosce-
dasticity means that the size of the difference between
two measurements changes with the size of the mean of
the two measurements. Logarithmic transformation is
suggested in the case of heteroscedasticity [23]. A non-
parametric approach is recommended when the paired
differences are not normally distributed [24].
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Simulation study
The simulation scenarios were inspired by our real data.
We simulated data assuming two different generating
mechanisms. In the first batch of simulations, we gener-
ated 1000 replicates from a normal distribution with a
fixed CV, hypothesizing n = 10 subjects each with p = 5
repeated measurements. In particular, for each subject
the p measurements were generated from Xi ∼N(μi, σi),
with μi ranging from 5 to 8 (10 equally spaced values),
and σi = μi∗CV, with CV ranging from 0.01 to 0.99 (50
equally spaced values). At each replication, the ICC was
estimated.
In the second batch of simulations, we generated 1000
replicates for n = 10 subjects each with p = 5 repeated
measurements from a mixed model. In particular, for
each subject the p measurements were generated from
Xi∼Npðμi; σ2BÞ , with μi∼Nðγ i; σ2BÞ . Different configura-
tions were considered by varying the overall mean γi = 1,
2…10, the between-subject variance σ2B ¼ 1; 4; 9 , and
within-variances σ2W varied, for fixed σ
2
B , to simulate a
true ICC sequence from 0.10 to 0.90 (9 equally spaced
values). At each replication, the CV was estimated.
Clinical data
The data analysed in the present paper arise from a mul-
ticentre observational study carried out at the Pediatric
Allergy and Immunology Service, Sapienza University
(Rome, Italy), and at the Pulmonary and Allergy
Pediatric Clinic of the CNR-IBIM (Palermo, Italy). The
study was approved by the local Institutional Ethics
Committee (Palermo, Italy, Approval Number: 7/2017),
and informed consent was obtained from all parents be-
fore study entry. Once approved, the study was regis-
tered on ClinicalTrials.gov (ID: NCT03286049). This
study was conducted in accordance with Good Clinical
Practice and the Declaration of Helsinki.
The sample size was estimated according to the
method illustrated by Zou [25] using the ICC.Sample.-
Size R package [26]. In order to test the null hypothesis
of ICC ≤ 0.20, considering an expected ICC of 0.70 based
on a previous study [8], five repeated measurements per
subject and a 90% statistical power and a 5% significance
level, a sample size of 10 subjects per group was re-
quired. Therefore, the study population comprised 50
children, i.e. 10 subjects for each of the following 5
groups:
– Healthy Children (HC)
– Children with non-allergic rhinitis (NAR), i.e. chil-
dren with rhinitis symptoms but without allergic
sensitization;
– Children with perennial allergic rhinitis (PAR), i.e.
children sensitized to perennial allergens;
– Children with seasonal allergic rhinitis outside
(SAR-O) and during (SAR-D) the pollen season, i.e.
children sensitized to seasonal allergens;
All the children underwent a standardized question-
naire including demographic characteristics and the core
questions on rhinitis of the International Study on
Childhood Asthma and Allergy (ISAAC) [27]. The ques-
tions referred to problems with sneezing, or a runny, or
blocked nose when the child did not have a cold or the
‘flu, “ever” and “in the past twelve months”.
The inclusion criteria were the following: (1) age 10–
16 years; (2) Total Five Symptoms Score (T5SS) > 5 for
children with AR and NAR; the T5SS included sneezing,
rhinorrhea, nasal itching, nasal obstruction and itchy
eyes (each symptom score ranging from 0 –absent- to 3
–severe-, so that the maximum possible score was 15);
T5SS > 5 at inclusion was established to ensure that pa-
tients were symptomatic. The exclusion criteria were the
following: medical diagnosis of nasal anatomic defects
(i.e., deviated septum) or nasal polyp disease; craniofacial
malformations; genetic diseases; medical diagnosis of
asthma according to GINA guidelines (http://ginasthma.
org); any acute illness in progress and in the month be-
fore the study; use of systemic steroids or antihistamines
in the past 4 weeks; use of any nasal therapy in the past
4 weeks; active smoking. The study involved three visits:
screening (visit 1, baseline), visit 2 (after 14 ± 3 days),
and a final assessment (visit 3, after 28 ± 3 days). At visit
1, patients were assessed for eligibility and recruited if
they met the inclusion criteria; then they underwent
physical examination and five AAR measurements for
each nostril. At visit 2 and 3, patients underwent one
AAR measure for each nostril. The performance of AAR
parameters in predicting patients’ current symptoms of
rhinitis was assessed through a ROC analysis [28]. The
Fig. 1 Simulated mean of the ICCs estimated given the CVs
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Table 1 Simulated means of the CVs with n = 10 and p = 5, for different σB, σW and overall mean μ
σB σW ICC μ = 1 μ = 2 μ = 3 μ = 4 μ = 5 μ = 6 μ = 7 μ = 8 μ = 9 μ = 10
1 3.00 0.10 10.043 3.748 1.367 0.829 0.642 0.531 0.447 0.39 0.349 0.311
2.00 0.20 8.384 1.517 0.773 0.563 0.442 0.367 0.316 0.274 0.243 0.220
1.53 0.30 5.449 1.033 0.613 0.455 0.360 0.300 0.256 0.223 0.198 0.179
1.22 0.40 7.652 0.844 0.527 0.392 0.311 0.257 0.221 0.193 0.172 0.154
1.00 0.50 4.553 0.74 0.467 0.35 0.277 0.230 0.197 0.172 0.153 0.138
0.82 0.60 2.237 0.661 0.422 0.316 0.254 0.209 0.179 0.158 0.14 0.126
0.65 0.70 1.548 0.607 0.393 0.294 0.234 0.194 0.166 0.147 0.129 0.117
0.50 0.80 1.372 0.566 0.365 0.274 0.218 0.181 0.156 0.137 0.121 0.109
0.33 0.90 1.381 0.53 0.344 0.258 0.206 0.171 0.146 0.129 0.114 0.103
2 6.00 0.10 15.189 31.267 7.798 4.253 1.897 2.664 0.999 0.831 0.734 0.645
4.00 0.20 39.446 8.42 4.951 1.589 0.971 0.774 0.654 0.562 0.496 0.448
3.06 0.30 17.292 4.903 42.938 1.016 0.761 0.618 0.524 0.454 0.401 0.363
2.45 0.40 14.228 3.779 1.431 0.835 0.643 0.525 0.449 0.392 0.346 0.312
2.00 0.50 11.276 3.226 1.008 0.741 0.571 0.468 0.399 0.348 0.309 0.278
1.63 0.60 7.749 2.987 0.908 0.654 0.52 0.423 0.362 0.319 0.281 0.254
1.31 0.70 8.677 1.681 0.83 0.605 0.478 0.392 0.334 0.295 0.260 0.235
1.00 0.80 6.518 1.544 0.761 0.562 0.445 0.366 0.314 0.276 0.244 0.219
0.67 0.90 8.934 1.292 0.713 0.527 0.419 0.344 0.295 0.260 0.230 0.207
3 9.00 0.10 20.852 17.435 12.41 10.566 24.537 3.814 2.238 2.669 1.740 1.075
6.00 0.20 17.845 15.271 8.064 4.595 2.732 1.501 1.089 0.891 0.774 0.695
4.58 0.30 22.043 11.754 5.801 2.702 1.561 0.994 0.825 0.704 0.616 0.556
3.67 0.40 16.047 9.100 5.331 1.661 1.052 0.829 0.694 0.603 0.527 0.476
3.00 0.50 55.490 6.752 3.387 1.563 0.911 0.726 0.612 0.531 0.470 0.422
2.45 0.60 147.388 6.271 1.847 1.155 0.819 0.651 0.554 0.486 0.426 0.385
1.96 0.70 13.316 5.836 1.746 1.058 0.744 0.600 0.509 0.447 0.393 0.355
1.50 0.80 12.635 7.708 1.421 0.927 0.689 0.559 0.478 0.418 0.369 0.332
1.00 0.90 10.619 4.621 1.207 0.841 0.647 0.524 0.447 0.394 0.347 0.312
Table 2 Characteristics of children by group at the baseline visit
HC NAR PAR SAR-O SAR-D All p-value*
n 10 10 10 10 10 50
Female 6 (60.00) 5 (50.00) 4 (40.00) 4 (40.00) 5 (50.00) 24 (48.00) 0.891
Age, years 11.30 ± 1.64 12.20 ± 1.14 12.00 ± 2.31 11.30 ± 1.49 12.00 ± 1.70 11.76 ± 1.67 0.486
Weight, Kg 56.20 ± 28.67 52.10 ± 11.72 50.90 ± 12.71 44.90 ± 7.48 44.90 ± 7.94 49.80 ± 15.72 0.490
Height, cm 155.15 ± 14.63 155.90 ± 9.62 154.50 ± 15.44 146.40 ± 7.90 151.45 ± 10.87 152.68 ± 12.07 0.375
BMI, Kg/m2 22.27 ± 6.34 21.22 ± 3.33 21.07 ± 2.70 20.83 ± 1.95 19.43 ± 1.11 20.97 ± 3.54 0.325
Parental history of rhinitis 4 (40.00) 4 (40.00) 6 (60.00) 5 (50.00) 7 (70.00) 26 (52.00) 0.605
Parental history of asthma 1 (10.00) 0 (0.00) 2 (20.00) 0 (0.00) 1 (10.00) 4 (8.00) 0.433
Parental smoking exposure# 3 (30.00) 5 (50.00) 2 (20.00) 0 (0.00) 3 (30.00) 13 (26.00) 0.143
Current symptoms of rhinitis** 6 (60.00) 8 (80.00) 9 (90.00) 10 (100.00) 10 (100.00) 43 (86.00) 0.054
Data are presented as mean ± SD for quantitative variables, n (%) for categorical variables. *Kruskal-Wallis test for quantitative variables, χ2 test for categorical
variables. #last 12 months; **ISAAC core question for rhinitis, n. 2: “In the past 12 months, has your child had a problem with sneezing, or a runny nose, or blocked
nose when he/she did not have a cold or the flu? Yes/No″
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estimation of the Area Under the Curve (AUC) was per-
formed by nonparametric ROC analysis and significance
was tested using the method described by DeLong et al.
[29]. Moreover, to avoid overrating the test performance
in ROC analysis, we performed a five-fold cross valid-
ation [30]. A p-value < 0.05 was considered to indicate a
statistically significant effect. Statistical analyses were
performed through R version 3.5.2; ICCs were computed
using the R package irr [15], the ROC curves were com-
puted using pROC [31].
Anterior active Rhinomanometry (AAR)
AAR was performed according to the ICSR guidelines,
using a RINOPOCKET ED200 (EUROCLINIC®, ITALY)
rhinomanometer. The rhinomanometer was calibrated ac-
cording to standard requirements. Rhinomanometry was
done in a temperature- and humidity-controlled room. A
small plastic catheter was inserted through a pierced piece
of tape and attached to flexible silicone tubing leading to
the pressure port of the meter. The foam was placed
across the contralateral nostril to measure the nasal
pharyngeal pressure, taking care not to interfere with the
nostril being tested. The tubing was brought out around
the side of the transparent mask. To perform rhinomano-
metry patients were asked to wear a face mask, close their
mouths and breathe. For each nostril a rhinogram was re-
corded which related inspiratory and expiratory nasal air-
flow to transnasal pressure. A retest was performed in all
patients. Measurements were performed by the same op-
erator using the same instrument and following the stand-
ard operation procedure according to Clement [32].
In reference to Ohm’s law (R = DeltaP / F), Rinopocket
uses the following: 1) a differential pressure transducer
− 25 to + 25 KPa (− 3.6 to + 3.6 psi) temperature com-
pensated to get DeltaP {other features are: accuracy (0 to
85 °C) = ±5.0%VFSS; sensitivity (V/P) = Typ 90mV/KPa;
response time (t r) = Typ 1.0 ms; offset stability = Typ
±0.5%VFSS}; 2) an airflow sensor compensated and amp-
lified (±300 SLPM) to get Flow; {other features are: re-
peatability and hysteresis = Typ ±0.035 Vdc; response
time (t r) = Typ 10 ms; Null voltage shift (25 °C to 5 °C
[77 °F to 41 °F] = Typ ±0.02 Vdc; 25 °C to 60 °C [77 °F to
140 °F]) = Typ ±0.02 Vdc; full scale output shift (25 °C to
5 °C [77 °F to 41 °F] = Typ ±2.5%reading; 25 °C to 60 °C
[77 °F to 140 °F]) = Typ ±2.5%reading}; 3) CPU =
STM32F373 32bit with internal A/D converter (3CH
16bit sigma-delta); 4) EDM software to calculate AAR
resistances at 150, 100, and 75 Pa (R 150 Pa, R 100 Pa
and R 75 Pa), total resistance and other parameters such
as max press, max flux, flux at 150,100, and 75 Pa. Ac-
cording to Broms, the quotient pressure-flow at the
standardized points were the curves cross the circle with
radius 2 which defined resistance 2 (R2) [33]. For each
nasal resistance, the AAR parameters considered were
inspiratory (R, L and R + L), expiratory (R, L and R + L),
total combined (total inspiratory + total expiratory).
Results
Simulation study
Figure 1 shows the mean of the ICCs estimated given
the CVs. The first batch of simulations emphasizes that
until the true CV was < 15%, ICC was greater than 0.50
Table 3 Nasal resistances (R2, R 75 Pa, R 100 Pa, R 150 Pa) by group
HC NAR PAR SAR-O SAR-D p-value
n 10 10 10 10 10
R2
Total Inspiratory 1.17 ± 0.52 1.18 ± 0.66 1.91 ± 1.69 2.56 ± 5.16 8.85 ± 11.77 0.024
Tota Expiratory 1.06 ± 0.50 1.20 ± 0.71 1.82 ± 1.52 1.86 ± 3.18 8.39 ± 10.69 0.010
Combined Total 2.23 ± 1.01 2.38 ± 1.32 3.74 ± 3.21 4.43 ± 8.33 17.24 ± 22.45 0.016
R75 Pa
Total Inspiratory 1.09 ± 0.47 1.06 ± 0.66 1.85 ± 1.53 2.20 ± 2.40 8.48 ± 8.57 < 0.001
Tota Expiratory 0.93 ± 0.48 0.80 ± 0.88 1.85 ± 1.59 2.38 ± 2.41 8.87 ± 7.63 < 0.001
Combined Total 2.02 ± 0.94 1.86 ± 1.46 3.69 ± 3.12 4.58 ± 4.81 17.36 ± 16.09 < 0.001
R 100 Pa
Total Inspiratory 1.09 ± 0.47 1.03 ± 0.66 1.80 ± 1.52 1.99 ± 2.43 7.98 ± 8.75 0.002
Tota Expiratory 0.93 ± 0.51 0.68 ± 0.84 1.56 ± 1.47 1.90 ± 1.80 6.41 ± 4.74 < 0.001
Combined Total 2.02 ± 0.96 1.71 ± 1.47 3.36 ± 2.97 3.89 ± 4.23 14.38 ± 12.85 < 0.001
R 150 Pa
Total Inspiratory 1.10 ± 0.61 0.81 ± 0.80 1.88 ± 1.80 2.57 ± 5.15 8.88 ± 11.77 0.019
Tota Expiratory 0.64 ± 0.52 0.62 ± 0.89 1.47 ± 1.63 1.98 ± 3.28 8.41 ± 10.68 0.006
Combined Total 1.74 ± 1.06 1.43 ± 1.67 3.35 ± 3.36 4.55 ± 8.42 17.28 ± 22.43 0.011
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even if data were generated under the CV model; overall,
ICC decreased as CV increased.
Table 1 reports the CVs estimated in the second batch
of simulations. For fixed ICC (for fixed σW and σB), the
estimated CVs decreased as the overall mean μ increased
as expected; however, most of the CVs were ≥ 0.15 also
for high ICC values. For fixed μ, the estimated CV de-
creased as σW decreased as expected; the only CVs < 0.15
were observed for quite large μ values.
Repeatability of AAR
At baseline, the characteristics of the children were similar
in the five groups (Table 2). In Table 3 the AAR parame-
ters given the five groups are shown. Significant differ-
ences were found for all AAR parameters among groups.
Table 4 reports the within-day ICCs for each AAR
parameter by group. Most of the ICCs were statistically
significant in all groups and they were > 0.20, which is
considered the cut-off value between poor and fair agree-
ment. Table 5 reports the coefficient of variation by group
for all AAR. Most of the CVs were ≥ 0.15, which would in-
dicate unacceptable repeatability.
Reproducibility of AAR
Figures 2, 3, 4 and 5 show the between-day reproducibil-
ity of total combined R2, R 75 Pa, R 100 Pa and R 150
Pa, for each group of children. Specifically, the first row
reports the reproducibility after 14 days from baseline
(visit 2), and the second row reports the reproducibility
after 28 days from baseline (visit 3). For all groups no
evidence of heteroscedasticity was found, and therefore
the statistical analysis was continued without logarithmic
transformation. Point distribution appeared to be ran-
dom, except for SAR-D, for which a decreasing trend
was observed, and SAR-O, for which most of the mea-
surements were clustered at small values.
Table 6 reports the CV and ICC values of Day 1 and
Day 14 and between Day 1 and Day 28 by group. An un-
acceptable reproducibility was found since all CVs
were ≥ 0.15 and most of the ICCs were not significant.
Table 4 Within-day ICCs by group for all the measured nasal resistances (R2, R 75 Pa, R 100 Pa, R 150 Pa)
Inspiratory Expiratory Combined Total
R L TOT R L TOT
R2 ICC p-value ICC p-value ICC p-value ICC p-value ICC p-value ICC p-value ICC p-value
HC 0.514 0.012 0.527 0.009 0.336 0.158 0.561 0.004 0.452 0.036 0.389 0.088 0.37 0.11
NAR 0.511 0.013 0.53 0.009 0.541 0.007 0.388 0.088 0.348 0.14 0.394 0.081 0.524 0.01
PAR 0.833 < 0.001 0.845 < 0.001 0.863 < 0.001 0.846 < 0.001 0.832 < 0.001 0.866 < 0.001 0.867 < 0.001
SAR-O 0.745 < 0.001 0.954 < 0.001 0.748 < 0.001 0.881 < 0.001 0.946 < 0.001 0.885 < 0.001 0.809 < 0.001
SAR-D 0.737 < 0.001 0.787 < 0.001 0.727 < 0.001 0.69 < 0.001 0.794 < 0.001 0.677 < 0.001 0.705 < 0.001
R 75 Pa
HC 0.469 0.027 0.432 0.049 0.241 0.352 0.47 0.027 0.55 0.006 0.303 0.216 0.271 0.282
NAR 0.36 0.123 0.619 0.001 0.502 0.015 0.787 < 0.001 0.54 0.007 0.68 < 0.001 0.67 < 0.001
PAR 0.953 < 0.001 0.838 < 0.001 0.928 < 0.001 0.962 < 0.001 0.783 < 0.001 0.914 < 0.001 0.926 < 0.001
SAR-O 0.802 < 0.001 0.784 < 0.001 0.802 < 0.001 0.816 < 0.001 0.718 < 0.001 0.776 < 0.001 0.79 < 0.001
SAR-D 0.866 < 0.001 0.399 0.077 0.817 < 0.001 0.756 < 0.001 0.836 < 0.001 0.726 < 0.001 0.782 < 0.001
R 100 Pa
HC 0.469 0.028 0.52 0.011 0.264 0.298 0.472 0.026 0.529 0.009 0.314 0.196 0.292 0.239
NAR 0.274 0.276 0.659 < 0.001 0.448 0.038 0.811 < 0.001 0.608 0.001 0.731 < 0.001 0.645 < 0.001
PAR 0.79 < 0.001 0.671 < 0.001 0.939 < 0.001 0.79 < 0.001 0.843 < 0.001 0.889 < 0.001 0.937 < 0.001
SAR-O 0.420 0.05 0.186 0.493 0.811 < 0.001 0.415 0.068 0.682 < 0.001 0.409 0.068 0.64 < 0.001
SAR-D 0.336 0.158 0.195 0.469 0.858 < 0.001 0.324 0.179 0.714 < 0.001 0.431 0.049 0.766 < 0.001
R 150 Pa
HC 0.513 0.012 0.591 0.002 0.383 0.094 0.464 0.03 0.247 0.339 0.337 0.156 0.363 0.118
NAR 0.561 0.004 0.655 < 0.001 0.667 < 0.001 0.834 < 0.001 0.623 0.001 0.768 < 0.001 0.738 < 0.001
PAR 0.828 < 0.001 0.841 < 0.001 0.879 < 0.001 0.859 < 0.001 0.568 0.004 0.777 < 0.001 0.851 < 0.001
SAR-O 0.743 < 0.001 0.952 < 0.001 0.747 < 0.001 0.883 < 0.001 0.713 < 0.001 0.884 < 0.001 0.816 < 0.001
SAR-D 0.739 < 0.001 0.785 < 0.001 0.727 < 0.001 0.687 < 0.001 0.807 < 0.001 0.674 < 0.001 0.703 < 0.001
Data are presented as ICC. Significant p-values are shown in bold
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Symptom data
Table 7 reports AUC and 95% CI for AAR parameters in
predicting current symptoms of rhinitis in the overall
study population. Of interest, in all the children report-
ing current symptoms of rhinitis a significant association
with two items of T5SS, such sneezing and nasal ob-
struction, were found (p = 0.024 and p = 0.021,
respectively).
Discussion
In this paper, two common approaches used for asses-
sing repeatability and reproducibility were compared;
the focus was on the misleading results obtained when
inappropriate tools are used. In fact, although the use of
the CV has largely been discouraged, this warning ap-
pears to be still ignored among most clinicians.
A simulation study showed that ICC values estimated
from data generated, assuming a given true CV, yielded
moderate repeatability until CV was < 15%, while when
data were generated from a mixed model, irrespective of
the magnitude of the true ICC, CV reported conflicting
results depending especially on the combination of mean
and variance used for generating the data [34]. Indeed,
when the mean value is close to zero, the coefficient of
variation approaches infinity and is therefore sensitive to
small changes in the mean. This is often the case if the
values do not originate from a ratio scale. Repeatability
and reproducibility should be assessed using a statistical
test highlighting reliability of the measurement and not
the differences between subjects.
Table 5 Within-day CV by group for all the measured nasal
resistances (R2, R 75 Pa, R 100 Pa, R 150 Pa)
Inspiratory Expiratory Combined
Total
R L Tot R L Tot
R2
HC 0.506 0.37 0.393 0.563 0.359 0.402 0.385
NAR 0.515 0.529 0.394 0.678 0.634 0.425 0.380
PAR 0.375 0.354 0.287 0.449 0.324 0.297 0.280
SAR-O 0.183 0.213 0.153 0.167 0.234 0.148 0.150
SAR-D 0.271 0.324 0.239 0.286 0.353 0.26 0.244
R 75 Pa
HC 0.710 0.449 0.47 0.811 0.994 0.591 0.500
NAR 0.736 0.630 0.586 0.923 0.803 0.708 0.613
PAR 0.454 0.419 0.309 0.77 0.627 0.471 0.354
SAR-O 0.389 0.359 0.313 0.271 0.321 0.205 0.239
SAR-D 0.270 0.402 0.341 0.301 0.274 0.285 0.293
R 100 Pa
HC 0.666 0.690 0.457 0.932 0.931 0.717 0.513
NAR 1.036 0.532 0.622 0.804 0.922 0.766 0.667
PAR 0.714 0.656 0.382 0.68 0.624 0.437 0.365
SAR-O 0.357 0.393 0.218 0.362 0.381 0.244 0.180
SAR-D 0.333 0.437 0.224 0.356 0.287 0.283 0.220
R 150 Pa
HC 0.591 0.557 0.489 1.414 1.330 1.004 0.584
NAR 1.191 0.968 1.032 0.775 1.390 0.818 1.063
PAR 0.789 0.569 0.599 0.461 0.686 0.654 0.537
SAR-O 0.189 0.217 0.159 0.307 0.521 0.355 0.260
SAR-D 0.264 0.327 0.243 0.315 0.350 0.270 0.250
Fig. 2 Bland-Altman plot: the difference between the Total R2 measurements of Day 1 and Day 14 (first row) and between Day 1 and Day 28
(second row) for each group. The broken lines represent 5 and 95% percentiles
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The motivating dataset provided a good example of
this; indeed, until now AAR repeatability has only been
studied in adults [8–10]. Two studies reported repeat-
ability in terms of CV, and only one reported both CV
and ICC. CVs computed for our clinical data, are similar
to other studies on healthy adults reporting unacceptable
repeatability [9] and reproducibility [10]. However, when
ICC is considered, our results suggest that AAR has
good repeatability. Similarly, Silkoff et al. reported con-
flicting results depending on the statistical tool used: in
particular good repeatability with ICC was observed
(0.76, 0.70 and 0.96 for right, left and combined nasal
Fig. 3 Bland-Altman plot: the difference between the Total R 75 (Pa) measurements of Day 1 and Day 14 (first row) and between Day 1 and Day
28 (second row) for each group. The broken lines represent 5 and 95% percentiles
Fig. 4 Bland-Altman plot: the difference between the Total R 100 (Pa) measurements of Day 1 and Day 14 (first row) and between Day 1 and
Day 28 (second row) for each group. The broken lines represent 5 and 95% percentiles
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Fig. 5 Bland-Altman plot: the difference between the Total R 150 (Pa) measurements of Day 1 and Day 14 (first row) and between Day 1 and
Day 28 (second row) for each group. The broken lines represent 5 and 95% percentiles
Table 6 CV and ICC between Day 1 and Day 14 (first column)
and between Day 1 and Day 28 (second column) by group
Day 14 Day 28
CV ICC p-value CV ICC p-value
R2
HC 0.395 0.004 0.719 0.429 0.228 0.461
NAR 0.525 0.475 0.171 0.366 0.646 0.046
PAR 0.352 0.71 0.022 0.256 0.306 0.362
SAR-O 0.337 0.55 0.106 0.341 0.681 0.031
SAR-D 0.201 0.781 0.007 0.239 0.776 0.008
R 75 Pa
HC 0.481 −0.167 0.861 0.459 0.245 0.439
NAR 0.799 0.142 0.567 0.508 0.493 0.154
PAR 0.402 0.742 0.014 0.347 0.179 0.521
SAR-O 0.417 0.378 0.275 0.531 0.482 0.164
SAR-D 0.333 0.534 0.118 0.372 0.549 0.106
R 100 Pa
HC 0.566 −0.239 0.903 0.469 0.308 0.36
NAR 0.663 0.316 0.35 0.529 0.531 0.121
PAR 0.465 0.769 0.009 0.398 0.262 0.417
SAR-O 0.356 0.437 0.21 0.459 0.551 0.105
SAR-D 0.23 0.681 0.032 0.255 0.708 0.023
R 150 Pa
HC 0.865 −0.440 0.973 0.682 0.390 0.261
NAR 1.106 0.007 0.716 0.709 0.494 0.153
PAR 0.535 0.738 0.015 0.592 0.302 0.368
SAR-O 0.274 0.494 0.153 0.376 0.625 0.057
SAR-D 0.206 0.772 0.008 0.234 0.765 0.010
Table 7 AUC and 95%CI for predicting current symptoms of
rhinitis
Current symptoms of rhinitis**
R2 AUC
95% CI
Total Inspiratory 0.741 0.576 0.905
Total Expiratory 0.689 0.495 0.884
Combined Total 0.708 0.532 0.885
R75 Pa
Total Inspiratory 0.822 0.699 0.945
Total Expiratory 0.746 0.57 0.922
Combined Total 0.792 0.639 0.944
R 100 Pa
Total Inspiratory 0.75 0.591 0.909
Total Expiratory 0.769 0.627 0.911
Combined Total 0.773 0.619 0.927
R 150 Pa
Total Inspiratory 0.701 0.536 0.865
Total Expiratory 0.735 0.604 0.866
Combined Total 0.723 0.572 0.875
**ISAAC core question for rhinitis, n. 2: “In the past 12 months, has your child
had a problem with sneezing, or a runny nose, or blocked nose when he/she
did not have a cold or the flu? Yes/No″
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resistance respectively), whereas, when CV was consid-
ered, unacceptable or poor repeatability was obtained for
right and left nasal resistance (CV = 15.9% and CV =
12.9%) [8]. On the other hand, when ICC was used to
assess reproducibility most of the ICCs were not signifi-
cant. However, in order to test the null hypothesis of
ICC ≤ 0.20, considering an expected ICC of at least 0.70
and two repeated measurements for subject with a 90%
statistical power and a 5% significance level, a sample
size of 21 subjects per group was needed [35]. Therefore,
the Bland and Altman plot is preferred, given the power-
ful visual representation of the degree of agreement and
the easy identification of bias, outliers, and any relation-
ship between the variance in measures with the size of
the mean [4]. Bland and Altman plots constructed for
our clinical data showed no evidence of heteroscedasti-
city and point distribution appeared to be random, ex-
cept for SAR-D and SAR-O. The difference in
reproducibility between groups is unexplained; however,
the required sample size to estimate reproducibility
using the Bland-Altman plot setting an expected mean
of differences 0.20, an expected standard deviation of
differences of 0.10 and a maximum allowed difference
between methods of 0.50, was of 26 subjects [22]. There-
fore, since the AAR repeatability in children with upper
airway obstructive symptoms has not been investigated
before, larger numbers of cases and more repeated
measurement in prospective are needed to better deter-
mine reproducibility.
The present paper might suggest that, due to the use
of inappropriate statistical tools, AAR repeatability and
reproducibility may have been underestimated in previ-
ous assessments. Overall, our results highlight the clin-
ical reliability of AAR both in healthy children and in
ones with rhinitis. Furthermore, we showed good per-
formance of AAR parameters in predicting current
symptoms of rhinitis in the overall study population.
This suggests that a more accurate reproducible meas-
urement well correlates with patient’s symptoms,
highlighting the additional value of AAR performance in
clinical practice.
Conclusions
Physicians dealing with clinical data should carefully
choose the most suitable statistical tools for assessing re-
peatability and reproducibility. The results of the present
study support the clinical reliability of AAR parameters
that showed good repeatability both in healthy and in
rhinitis children.
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